中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 合肥物质科学研究院
  3. 中国科学院合肥物质科学研究院
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

文献类型：期刊论文

作者Jiang, Zongru2,3; Wang, Li2,3; Liu, Xuesong2,3; Chen, Cheng2,3; Wang, Beilei2,3; Wang, Wenliang2,3; Hu, Chen2; Yu, Kailin2; Qi, Ziping2; Liu, Qingwang4
刊名ACTA PHARMACEUTICA SINICA B
出版日期2020-03-01
卷号10
ISSN号2211-3835
关键词Cancer VEGFR2 kinase Kinase inhibitor Angiogenesis Inhibitor selectivity
DOI10.1016/j.apsb.2019.10.004
通讯作者Hong, Guangchen(2297023869@qq.com) ; Wang, Wenchao(wwcbox@hmfl.ac.cn) ; Liu, Qingsong(qsliu97@hmfl.ac.cn)
英文摘要Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which might result in target-associated side effects and therefore limited clinical toleration. Highly selective VEGFR inhibitors are still highly demanded from both basic research and clinical application point of view. Here we report the discovery and characterization of a novel VEGFR2 inhibitor (CHMFL-VEGFR2-002), which exhibited high selectivity among structurally closed kinases including PDGFRs, FGFRs, CSF1R, etc. CHMFL-VEGFR2-002 displayed potent inhibitory activity against VEGFR2 kinase in the biochemical assay (IC50 = 66 nmol/L) and VEGFR2 autophosphorylation in cells (EC(50)s similar to 100 nmol/L) as well as potent anti-proliferation effect against VEGFR2 transformed BaF3 cells (GI(50) = 150 nmol/L). In addition, CHMFL-VEGFR2-002 also displayed good anti-angiogenesis efficacy in vitro and exhibited good in vivo PK (pharmacokinetics) profile with bioavailability over 49% and anti-angiogenesis efficacy in both zebrafish and mouse models without apparent toxicity. These results suggest that CHMFL-VEGFR2-002 might be a useful research tool for dissecting new functions of VEGFR2 kinase as well as a potential anti-angiogenetic agent for the cancer therapy. (C) 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
WOS关键词RENAL-CELL CARCINOMA ; SUNITINIB ; EFFICACY ; HYPOTHYROIDISM ; GROWTH ; SAFETY
资助项目National Natural Science Foundation of China[81773777] ; National Natural Science Foundation of China[81673469] ; National Natural Science Foundation of China[81603123] ; National Natural Science Foundation of China[81803366] ; China Postdoctoral Science Foundation[2018T110634] ; China Postdoctoral Science Foundation[2018M630720] ; Anhui Province Postdoctoral Science Foundation[2018B279] ; CASH-IPS Director's Fund[BJPY2019A03] ; Key Program of 13th five-year plan, CASHIPS[KP-2017-26]
WOS研究方向Pharmacology & Pharmacy
语种英语
出版者INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
WOS记录号WOS:000518042300008
资助机构National Natural Science Foundation of China ; China Postdoctoral Science Foundation ; Anhui Province Postdoctoral Science Foundation ; CASH-IPS Director's Fund ; Key Program of 13th five-year plan, CASHIPS
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/103875]  
专题中国科学院合肥物质科学研究院
通讯作者Hong, Guangchen; Wang, Wenchao; Liu, Qingsong
作者单位1.Precis Med Res Lab Anhui Prov, Hefei 230088, Peoples R China
2.Chinese Acad Sci, Hefei Inst Phys Sci, High Magnet Field Lab, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China
3.Univ Sci & Technol China, Hefei 230026, Peoples R China
4.Chinese Acad Sci, Precis Targeted Therapy Discovery Ctr, Inst Technol Innovat, Hefei Inst Phys Sci, Hefei 230088, Peoples R China
5.Qingdao Shinan Dist Peoples Hosp, Qingdao 266002, Peoples R China
6.Anhui Univ, Inst Phys Sci & Informat Technol, Hefei 230601, Peoples R China
推荐引用方式
GB/T 7714		 Jiang, Zongru,Wang, Li,Liu, Xuesong,et al. Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent[J]. ACTA PHARMACEUTICA SINICA B,2020,10.
APA Jiang, Zongru.,Wang, Li.,Liu, Xuesong.,Chen, Cheng.,Wang, Beilei.,...&Liu, Qingsong.(2020).Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent.ACTA PHARMACEUTICA SINICA B,10.
MLA Jiang, Zongru,et al."Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent".ACTA PHARMACEUTICA SINICA B 10(2020).

入库方式： OAI收割

来源：合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。